Trial of Covaxine: India’s COVID 19 Vaccine  

COVID 19 has created a pandemic situation all around the world and India is listed in the third position among the worst affected country by this virus. Till now there is no proper vaccine or medicine to cure this. Many world-famous research institutes are doing the clinical trials of the corona vaccine. In this article, we will talk about India’s COVID 19 vaccine trial.

Development of Covaxine

Covaxine is known to be India’s first potential vaccine for COVID 19 developed by the Bharath Biotech International Limited (BBIL).  The clinical trials in human beings have started from 15 July as per the report of Hindustan Times.

Along with the Hyderabad-based pharmaceutical company, the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) for 375 patients in twelve hospitals in different parts of the country.

The hospitals where the vaccine trials have started include All India Institute of Medical Sciences (AIIMS) Delhi, AIIMS Patna, King George Hospital in Visakhapatnam, Post Graduate Institute of Medical Sciences (PGIMS) in Rohtak, Jeevan Rekha Hospital in Belgaum, Gillurkar Multispeciality Hospital in Nagpur, Rana Hospital in Gorakhpur, SRM Hospital in Chennai, Nizam Institute of Medical Sciences in Hyderabad, Kalinga Hospital in Bhubaneswar, Prakhar Hospital in Kanpur and a hospital in Goa by undertaking safety measures as per the instructions of ICMR.


During the first trial stage, it is observed that there is no critical side effects for the vaccine injected persons. But it is not yet concluded that it will resist the virus or not at this stage. The vaccine manufacturer has said that these are randomized double-blind clinical trials.

Bharat Biotech is among the seven Indian firms working on Covid-19 vaccines. And it was the first to get the regulatory nod to begin phase 1 and phase 2 human trials to test the vaccine for efficacy and safety.

Leave a Reply

Your email address will not be published. Required fields are marked *